AGC Biologics’ Success Highlights Colorado’s Appeal for Life Sciences Companies
AGC Biologics, a global CDMO, operates two major facilities in Colorado. After investing in its Boulder facility in 2020 with support from the state of Colorado and regional economic development groups, the company acquired its Longmont facility in 2021. The recent expansion of AGC Biologics’ Longmont facility enhances the region’s appeal for life sciences companies. Three new Grade B cell therapy suites, featuring cutting-edge modular clean room design and flexible capacity configuration, strengthens the Longmont site’s cell therapy capabilities. This enhancement complements the existing viral vector expansion completed in 2022, which included a range of bioreactor sizes for product development (AMBR, 10L and 50L), and a complete range of commercial manufacturing capacities (50L, 200L, 500L and 2000L), enabling the site to provide support for the entire lifecycle of a product.
The expansion enables AGC Biologics to provide end-to-end cell therapy development and manufacturing services in one location, offering unique benefits to developers seeking comprehensive support for bringing their products to market. With additional space available, AGC Biologics is well-prepared to further expand its cell therapy capabilities to meet the growing market demand. This expansion reinforces Colorado’s position a leading hub for cutting-edge biotech innovation and commercialization.
